IL17A and lung cancer: Deletion or blockade of IL-17 suppressed the tumor-promoting inflammation, reactivated tumor immunosurveillance, and reduced the frequency of tumorigenesis in lung cancer models.460,861 Accordingly, patients with CRC could be benefited by cancer immunotherapy using the anti-IL-17 approach as adjuvant therapies, which would contribute to the inhibition of both IL-17-mediated tumor promotion and T-cell exclusion.